Related Experiment Video
Updated: Jun 13, 2026
08:45
Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
Published on: May 10, 2022
Pregnancy-induced antithrombin deficiency
Mamoru Morikawa1, Takashi Yamada, Takahiro Yamada
1Department of Obstetrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan. mmamoru@med.hokudai.ac.jp
Journal of Perinatal Medicine
|May 7, 2010
Summary
Pregnancy-induced antithrombin deficiency (PIATD) is linked to enhanced coagulation and altered body weight, even without hypertension. Monitoring antithrombin (AT) activity can identify these risks during pregnancy.
Area of Science:
- Obstetrics and Gynecology
- Hematology
- Perinatology
Background:
- Pregnancy-induced antithrombin deficiency (PIATD) is a condition affecting blood coagulation.
- Understanding its laboratory features and impact on water metabolism is crucial for maternal health.
- Pregnancy-induced hypertension (PIH) is a common complication, and its overlap with PIATD requires investigation.
Purpose of the Study:
- To characterize the laboratory features of women with PIATD.
- To investigate the water metabolism in women with PIATD.
- To determine the relationship between PIATD and PIH.
Main Methods:
- Retrospective study of 1493 women, identifying 114 with PIATD and/or PIH.
- Comparison of laboratory variables (hematocrit, fibrinogen, D-dimer, etc.) and body weight between groups.
- PIATD defined as antithrombin (AT) activity ≤65% of normal.
Main Results:
- 19.4% of women with PIH also developed PIATD; 33 women had PIATD without PIH.
- Women with PIATD showed enhanced coagulation-fibrinolysis and greater postpartum hematocrit reduction.
- Postpartum weight decrease was smaller in women with PIATD, regardless of hypertension.
Conclusions:
- Decreased AT activity can occur without hypertension in PIATD.
- PIATD is associated with decreased plasma volume and enhanced coagulation-fibrinolysis, even without PIH.
- Monitoring AT activity aids in identifying pregnant women with these risks.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...